Wilson disease is a rare genetic condition, in which the liver loses the ability to effectively remove copper, allowing it to accumulate in the body. This toxic buildup affects the liver, brain, eyes and kidneys and is particularly bad for mitochondria, the cell's all-important power plants.
Wilson disease treatments have included removing copper from patients' bodies (copper chelation) and dietary restrictions to reduce copper intake. But now, UC Davis Health scientists are looking at a different therapeutic approach: mitigating the condition's effects on mitochondria.
In a study published in Nature Scientific Reports, researchers showed that metformin, a common treatment for type 2 diabetes, could help control mitochondrial dysfunction in an animal model of Wilson disease. This effect was particularly noticeable in female mice.
"We've been exploring the possibility that we could retask existing drugs to improve mitochondrial function in people with Wilson disease," said Valentina Medici, first author on the study and professor of gastroenterology and hepatology. "There are several drugs that can do this, but metformin is particularly interesting because it's available on the market and extensively studied."
Investigating mitochondria
UC Davis Health researchers are in a unique position to study this condition: the Wilson Disease Association has designated the health system one of 11 Centers of Excellence. Medici and colleagues including Cecilia Giulivi, professor of Molecular Biosciences in the UC Davis Weill School of Veterinary Medicine and senior author on the paper, have focused their research on mitochondrial bioenergetics: the ability to produce enough energy to power cells.
While Wilson disease is one of the few rare genetic conditions to even have treatments, copper chelation has shown only limited efficacy and completely neglects the disease's mitochondrial impacts.
Metformin is safe, inexpensive and has been a mainstay in type 2 diabetes treatment for decades. While the drug is prized for its ability to lower blood sugar levels, it can also bind to metal molecules, including copper. This often-overlooked capability intrigued the research team.
"We have seen mitochondrial dysfunction in Wilson disease patients and preclinical models," said Medici. "That inspired us to begin looking for drugs that improve mitochondrial bioenergetics, and metformin seems quite promising."
The gender mystery
In the study, the female mouse models experienced more severe mitochondrial injury than their male counterparts. However, the females were also more responsive to metformin, with higher levels in the blood. In addition, after metformin treatment, mitochondria in the females became larger, rounder and smoother.
Human Wilson disease patients have similar dynamics, with women often experiencing more severe symptoms, for yet-unknown reasons. Ongoing research may provide answers.
Still, the possibility that metformin, and perhaps other drugs, could treat this condition clearly warrants further investigation. Wilson disease symptoms often appear later in childhood, and sometimes in middle age, making it particularly amenable to early interventions. A combination of early screening and access to safe and inexpensive therapies could delay or possibly prevent symptoms.
"The ideal situation is to diagnose patients early," said Medici. "There is some push to add Wilson disease to the list of conditions for newborn screening. We could potentially prevent severe liver disease, acute liver failure and the neuropsychiatric symptoms, which are very difficult to treat in adult patients."